© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 08, 2008
To evaluate the interactions between the weight loss drug, sibutramine, and different antihypertensive treatments, we randomly assigned 171 subjects taking 3 antihypertensive treatment regimens to receive sibutramine or placebo. Our study showed for the first time that combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker is more advantageous than a ß blocker/diuretic-based-regimen with regard to supporting the weight-reducing actions and metabolic changes induced by sibutramine.
Research Suggests Pediatric Psoriasis Linked to Anxiety, Depression
Esketamine Infusion May Prevent Post-Surgery Sleep Disturbances
Study Suggests PCSK9 Inhibitors May Reduce Psoriasis Risk